OS Therapies' OSAH subsidiary receives USDA guidance on commercial deployment pathway for OST-HER2 canine osteosarcoma treatment

OS Therapies' OSAH subsidiary received guidance from the U.S. Department of Agriculture on the commercial deployment pathway for OST-HER2 to treat canine osteosarcoma.

Detected & updated continuously · Source: Nebula